Vicriviroc + MK2048 + Progestin Vaginal Ring
Description: A vaginal ring whose mechanism of action is CCR5 inhibitor, integrase inhibitor and a progestin for protection against HIV and pregnancy.
Delivery Method: Vaginal Ring
Active Pharmaceutical Ingredient (API):
Inactive material: EVA
Multipurpose Preventive Technology (MPT): Yes
Project Phase: Pre-Clinical and Clinical Development
Development Stage: Pre-clinical
Active Development: Unknown
- Phase I study of 2-ARV IVR prototype completed in 2016.
- Merck announced that it would discontinue development of its investigational CCR5 antagonist vicriviroc for the treatment of HIV infection in both treatment-naive and treatment-experienced patients, due to unimpressive results in clinical trials.